

Lao People's Democratic Republic HIV Country Profile 2022


WHO/UCN/HHS/21.10

Year

Value

Lao People's Democratic Republic

Demographic and socioeconomic data Total Population (2021) GNI per capita, PPP (2021) 8 150 US\$ 7.425 million Health expenditure, total (% of GDP) Maternal mortality per 100 000 live births (2019)(2017)3% 185 Life expectancy at birth (2021) Health expenditure per capita (2019) 38.7 years 68 US\$ Total fertility rate (births per woman) Human Development Index Value (2019) (2021)




tal fertility rate (births per woman) (2021)


2.5


Estimated % of pregnant women living with HIV who received ARVs for PMTCT (2021)

Estimated ART coverage children and adults (2021)



Estimated number of people dying from HIV -related causes





Epidemiological HIV data (2021)

Trend since 2010

Estimated number of women (15+) living with HIV

Estimated number of people newly infected with HIV

Estimated number of people living with HIV

Estimated number of people dying from HIV-related causes

Estimated number of children aged 0 to 14 living with HIV

530

Estimated incidence rate per 1000 uninfected population

Estimated adult (15-49) prevalence


0.3%

Antiretroviral therapy (ART) (2021)

Elimination of mother-to-child transmission (EMTCT) of HIV &

Trend since 2010 (147%)

▼		
Reported number of pregnant women living with HIV who received antiretrovirals for PMTCT	179	2021
Final transmission rate including breastfeeding period ³ (%)	20.6%	2021
Estimated percentage of pregnant women living with HIV who received antiretrovirals for PMTCT ² (%)	100%	2021
Antenatal care coverage - at least one visit (%)	78.4%	2017
Antenatal care coverage - at least four visits (%)	62.2%	2017
Antenatal care attendees who were tested for syphilis (%)	N/A	2017
Antenatal care attendees who tested positive for syphilis and who received benzathine penicillin IM (%)	N/A	N/A
Antenatal care attendees who tested positive for syphilis (%)	0.76%	2009
% of pregnant women with known HIV status	<1%	202
% of infants born to women living with HIV receiving a virological test within two months of birth (EID) ¹ (%)	64.7%	2021




(green, orange, red) is used to indicate if the country is on target to meet 2020 targets: 190% 295% 3Less than 5

Key populations (2021)

First line	Second line		
Median annual price of ARV drug regimens for adults			
Percentage of people who inject drugs receiving OST	N/A		
Percentage condom use among sex workers with most recent client	90.6%		
Needles distributed per person who inject drugs per year	3		
HIV prevalence among sex workers (%)	0.8%		
HIV prevalence among people who inject drugs (%)	N/A		
HIV prevalence among men who have sex with men (%)	4.1%		

Value



National HIV policies and plans (2022)				
Indicator	Value Value			
Implementation of national policy on HIV self-testing (HIVST)	HIVST policy and pilots			
Treatment initiation threshold among adults and adolescents	Treat all regardless of CD4 count			
Implementation of treat all policy among adults and adolescents	Implemented countrywide (>95% of treatment sites)			
Implementation of lifelong ART for pregnant & breastfeeding women	Implemented			
Treatment initiation threshold among children	Treat all, regardless of age			
Adoption of WHO 2017 recommendation on rapid initiation of ART	Rapid initiation within 7 days of HIV diagnosis			
National policy supporting community delivery of ART	No policy			
Adoption of WHO recommendation to offer package of interventions for patients with advanced HIV disease	Fully adopted			
Policy on the frequency of clinic visits for adults who are doing well on antiretroviral therapy	Every 3 months for adults who are doing well on ART			
Policy on how frequently adults who are doing well on antiretroviral therapy should pick-up antiretroviral medicine (MMD)	Every 3 months for adults who are doing well on ART			
Dolutegravir (DTG) as part of 1st line ARVs for adults and adolescents	DTG introduced in national guidelines and procurement initiated			
Implementation of national policy on viral load monitoring	Implemented countrywide (>95% of treatment sites)			
Availability of point-of-care viral load testing	Not available			
National M&E plan or strategy for HIV	Stand-alone HIV monitoring and evaluation strategy or plan			

WHO (2022), Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat (2022), UNICEF Data (2022), United Nations Development Programme (2022), Spectrum estimates UNAIDS/WHO (2022), World Bank (2022)

Sources: Global AIDS Monitoring UNAIDS/WHO/UNICEF (2022), Global Health Expenditure Database WHO (2022), Global Health Observatory WHO (2022), Global Price Reporting Mechanism

Definition of acronyms: PLHIV = People living with HIV, HIV = Human Immunodeficiency Virus, AIDS = Acquired Immunodeficiency Syndrome, ART = Antiretroviral Therapy,

ARVs = Antiretrovirals, PMTCT = Prevention of Mother-to-Child Transmission, EID = Early Infant Diagnosis, OST = Opioid Substitution Therapy, MMD = Multi-month Dispensing